Document is current

Article History

Received: 12 December 2024

Accepted: 28 February 2025

First Online: 25 April 2025

Declarations

:

: Franz Weber (FWb): no competing interest. Christina Scharf (CS): CS received speaker honoraria from CytoSorbents Europe GmbH. Linda Brita Sofia Aulin (LA): no competing interest. Ferdinand Weinelt (FWe): no competing interest. Michael Paal (MP): no competing interest. Gerd Mikus (GM): no competing interest. Michael Vogeser (MV): no competing interest. Katharina Habler (KH): no competing interest. Wilhelm Huisinga (WH): WH received research grants from an industry consortium (AbbVie Deutschland GmbH & Co. K.G., AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co. KG., F. Hoffmann-La Roche Ltd., Merck KGaA, Novo Nordisk A/S and Sanofi) for the graduate research training program PharMetrX. Michael Zoller (MZ): MZ received research support from CytoSorbents Europe GmbH, consulting fees from Gilead and speaker honoraria from MSD. Robin Michelet (RM): no competing interest. Charlotte Kloft (CK): CK received research grants from an industry consortium (AbbVie Deutschland GmbH & Co. K.G., AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co. KG., F. Hoffmann-La Roche Ltd., Merck KGaA, Novo Nordisk A/S and Sanofi) for the graduate research training program PharMetrX, from the Innovative Medicines Initiative-Joint Undertaking (“DDMoRe”), from H2020-EU.3.1.3 (“FAIR”), Diurnal Ltd. and the Federal Ministry of Education and Research within the Joint Programming Initiative on Antimicrobial Resistance Initiative (“JPIAMR”), all outside the submitted work. Uwe Liebchen (UL): UL received consulting honoraria from CytoSorbents Europe GmbH and Medows Sàrl, and was part of an advisory board of Roche Diagnostics International Ltd.

: Ethics approval and consent were obtained from the Institutional Review Board of the Medical Faculty of the Ludwig-Maximilians-University Munich, Germany (registration number 18-578).

: Not applicable.